Herpes Zoster Infection Treatment Market Overview
The Herpes Zoster Infection Treatment Market was valued at approximately USD 4.8 billion in 2025 and is projected to reach USD 7.2 billion by 2035, registering a CAGR of 4.1% during the forecast period. Increasing incidence of herpes zoster, rising geriatric population, advancements in antiviral therapies and vaccines, growing awareness and education, and expansion of treatment options are supporting market growth.
Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. It typically presents as a painful rash and can lead to complications such as postherpetic neuralgia. Treatment approaches include antiviral medications, pain relief medications, and preventive vaccines.
The increasing prevalence of herpes zoster due to an aging population is a key driver. As individuals age, their immune systems weaken, making them more susceptible to infections, including shingles. According to the Centers for Disease Control and Prevention (CDC), approximately one out of three individuals will develop herpes zoster in their lifetime, with the highest risk seen in people over the age of 50. The World Health Organization projects that by 2030, the number of people aged 60 years and older will surpass 1 billion worldwide.
Advancements in treatment options are further accelerating market expansion. The development of novel antiviral medications, such as valacyclovir and famciclovir, has improved patient outcomes by reducing the duration and severity of symptoms when administered within 72 hours of rash onset. Ongoing research and development initiatives continue to explore combination therapies and targeted immunotherapy solutions.
Growing awareness and vaccination campaigns are also driving market growth. The introduction of the herpes zoster vaccine, Shingrix, has resulted in a significant uptick in vaccination rates, especially among eligible populations aged 50 and above. According to the CDC, nearly 60% of adults aged 60 or older have received a shingles vaccine in recent years.
The financial burden associated with treating herpes zoster and its complications is another significant market driver. According to a study published in the Journal of Medical Economics, the total annual cost burden of herpes zoster and postherpetic neuralgia is estimated to be over USD 1 billion in the United States alone. Early intervention can lower the long-term costs associated with complications and hospitalizations.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=617843
Bayer
Merck
Pfizer
Novartis
Eli Lilly
Teva Pharmaceuticals
Mylan
Medimmune
Bausch Health
Amgen
Johnson & Johnson
GSK
AbbVie
Sanofi
Hoffmann-La Roche
AstraZeneca
The competitive landscape of the Herpes Zoster Infection Treatment Market is characterized by continuous innovation, strategic collaborations, and expansion of treatment and vaccination capabilities. Leading companies are focusing on developing novel antiviral therapies, improving vaccine accessibility, and expanding distribution networks globally.
Companies are investing in research and development to bring forth advanced treatment options, while strategic partnerships aim to enhance manufacturing capacity and distribution reach. Bayer has launched a novel oral antiviral for herpes zoster infections, expanding at-home treatment options. GSK announced a strategic partnership with Teva Pharmaceuticals to expand manufacturing capacity and distribution of Shingrix, aiming to broaden access to herpes zoster vaccination in low- and middle-income countries. Sanofi announced a multi-year contract win to supply herpes zoster vaccines to public health programs across Europe and Asia.
By treatment type, the market includes Antiviral Medications, Pain Relief Medications, and Vaccines. Antiviral Medications hold a dominant position, valued at USD 2,400 million in 2024 and projected to reach USD 3,600 million by 2035, due to their efficacy in mitigating symptoms and preventing postherpetic neuralgia. Pain Relief Medications are also an important segment, seeing steady expansion as they play a vital role in alleviating discomfort. Vaccines are experiencing moderate increases in interest, as preventive measures gain recognition in the healthcare community.
By route of administration, the market includes Oral, Topical, and Injectable. Oral treatments are gaining traction due to their convenience and patient compliance, representing 43.8% of the market in 2024. Topical applications are favored for localized relief, while injectable forms are becoming increasingly relevant for severe cases.
By end user, the market includes Hospitals, Clinics, and Homecare. Hospitals serve as specialized care centers where advanced treatment options and monitoring are available. Clinics provide accessible treatment for patients seeking relief from acute symptoms and ongoing management. Homecare services are increasingly becoming popular as they offer convenience and personalized care for recovery at home.
By age group, the market includes Children, Adults, and Elderly. The elderly population, being the most significantly impacted group, shows a higher incidence of herpes zoster, making them a pivotal focus area for the market. Adults often encounter increased risks due to stress and health conditions, while children, though less frequently affected, require specific care to mitigate complications.
➤➤Explore Our Latest Related Reports:
